During the past decade, Hospital Evangélico de Cachoeiro de Itapemirim conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hospital Evangélico de Cachoeiro de Itapemirim" are "Cancer" (1 trials) and "Non-small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Hospital Evangélico de Cachoeiro de Itapemirim" in a lesser frequency.

Most popular intervention types in "Hospital Evangélico de Cachoeiro de Itapemirim" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Darolutamide (Nubeqa, BAY1841788)" (1 trials), "Docetaxel" (1 trials) and "Tislelizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Evangélico de Cachoeiro de Itapemirim" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital Evangélico de Cachoeiro de Itapemirim". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Hospital Evangélico de Cachoeiro de Itapemirim, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Evangélico de Cachoeiro de Itapemirim, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".